The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Keros Therapeutics Inc (NASDAQ: KROS) closed the day trading at $20.13 down -3.36% from the previous closing price of $20.83. In other words, the price has decreased by -$3.36 from its previous closing price. On the day, 0.58 million shares were traded. KROS stock price reached its highest trading level at $21.05 during the session, while it also had its lowest trading level at $19.85.
Ratios:
For a better understanding of KROS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.29. For the most recent quarter (mrq), Quick Ratio is recorded 29.86 and its Current Ratio is at 29.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $26.
On June 10, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’25 when Pontifax Management 4 G.P. (20 sold 4,787,331 shares for $17.75 per share. The transaction valued at 84,975,125 led to the insider holds 0 shares of the business.
ADAR1 Capital Management, LLC sold 5,389,264 shares of KROS for $95,659,436 on Oct 15 ’25. The 10% Owner now owns 0 shares after completing the transaction at $17.75 per share. On Sep 12 ’25, another insider, Rovaldi Christopher, who serves as the Affiliate of the company, bought 85,306 shares for $15.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 613281920 and an Enterprise Value of -62761032. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.57 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at -0.254 whereas that against EBITDA is -1.31.
Stock Price History:
The Beta on a monthly basis for KROS is 0.86, which has changed by 0.22313559 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $22.55, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is 16.74%, while the 200-Day Moving Average is calculated to be 36.84%.
Shares Statistics:
Over the past 3-months, KROS traded about 992.10K shares per day on average, while over the past 10 days, KROS traded about 699480 shares per day. A total of 40.63M shares are outstanding, with a floating share count of 28.40M. Insiders hold about 6.77% of the company’s shares, while institutions hold 106.59% stake in the company. Shares short for KROS as of 1764288000 were 3228958 with a Short Ratio of 3.25, compared to 1761868800 on 5862479. Therefore, it implies a Short% of Shares Outstanding of 3228958 and a Short% of Float of 20.47.
Earnings Estimates
A detailed examination of Keros Therapeutics Inc (KROS) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.45 and low estimates of -$0.65.
Analysts are recommending an EPS of between $2.68 and $2.1 for the fiscal current year, implying an average EPS of $2.33. EPS for the following year is -$2.89, with 8.0 analysts recommending between -$0.74 and -$4.71.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $253.68M, while the lowest revenue estimate was $234.26M, resulting in an average revenue estimate of $246.08M. In the same quarter a year ago, actual revenue was $3.55M
